NKTR
Nektar Therapeutics
A biopharmaceutical company that uses a technology called PEGylation—attaching polymer chains to drugs so they dissolve better and last longer in the body—and now focuses on therapies for immune and inflammatory diseases. It began in 1990 as Inhale Therapeutic Systems, a firm known for inhaled drug delivery, and took the name Nektar in 2003 to signal a broader mission. The name plays on "nectar," a sweet nod for a company whose famous early product was the inhaled insulin Exubera.
CUSIP: 640268108HealthcareUS1 holder1 derivative reporter
Total Value
$9.62M
Total Shares
197.0K
Net Share Change
-780
Activity
1 selling
Investor
Value
Shares
Weight
Change
